Biotech stocks rally as FDA biologics chief Prasad to depart
Leadership change raises hopes for smoother drug approvals after regulator's controversial decisions
Biotechnology shares surged across multiple names on Monday following news that Dr. Vinay Prasad, the head of the US Food and Drug Administration's Center for Biologics Evaluation and Research (CBER), will leave his position in April. The announcement triggered sharp gains for companies that had faced regulatory hurdles under his leadership, including gene therapy specialists and vaccine developers.
uniQure led the rally, with shares jumping 19% to $16.99. The Dutch gene therapy company had been at odds with the FDA after Prasad's office denied expedited review for its AMT-130 treatment for Huntington's disease, despite earlier indications that accelerated approval might be possible without a placebo control. Moderna added 1.4% to $53.28, while Solid Biosciences climbed 12% to $7.57 and Capricor Therapeutics gained 9%.
The market reaction reflects investor hopes for a more predictable regulatory environment. Prasad's tenure, which began in May 2025 and was marked by a brief departure that summer before his return, was characterized by what analysts at William Blair described as "idiosyncratic decisions and interventions on drug reviews." His approach drew criticism from biotech companies and investors for its strict interpretation of clinical trial requirements, particularly for rare diseases where traditional randomized controlled trials are often impractical.
The implications of Prasad's departure could be significant for several high-profile drug applications. Moderna's mRNA-1010 influenza vaccine, which initially received a refuse-to-file letter from the FDA under Prasad's leadership, could now qualify for full approval in adults 65 and older without requiring an additional costly efficacy study, according to William Blair analysts. Similarly, the change may benefit rare disease sponsors that rely on single-arm studies and external control groups for regulatory approval—methods that Prasad had personally challenged.
The CBER division oversees approval of a wide range of cutting-edge treatments, including cancer drugs, gene therapies, and vaccines. Its decisions can make or break biotech companies, particularly smaller firms developing treatments for rare diseases with limited patient populations. The prospect of a more industry-friendly approach has investors betting that previously stalled applications could move forward under new leadership.
Other companies seeing positive momentum included Regenxbio and Crispr Therapeutics, which both posted gains. The broad-based rally suggests investors are positioning for a potential shift in FDA strategy that could benefit multiple drug developers across the biotechnology sector.
The FDA has not yet announced Prasad's successor. The timing of the leadership change—coming as the agency navigates a pipeline of increasingly complex gene and cell therapies—will be closely watched by the industry. For now, investors are celebrating the prospect of reduced regulatory friction and what analysts at William Blair called "greater predictability" in the drug approval process.